Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Business Wire 6 days ago

MindMed to Participate in Upcoming Investor Conferences

Business Wire 11 days ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Business Wire November 7, 2024

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Business Wire October 24, 2024

MindMed Announces New Employee Inducement Grants

Business Wire September 9, 2024

MindMed to Participate in September Investor Conferences

Business Wire September 4, 2024

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Business Wire August 13, 2024

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Business Wire August 9, 2024

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Business Wire August 9, 2024

MindMed to Present at Canaccord Genuity's 44th Annual Growth Conference

Business Wire August 6, 2024

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

Business Wire August 6, 2024

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Business Wire July 29, 2024

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Business Wire July 17, 2024

MindMed to be Included in Russell 2000® and Russell 3000® Indexes

Business Wire June 28, 2024

MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Business Wire June 21, 2024

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

Business Wire June 20, 2024

MindMed to Participate in June Conferences

Business Wire May 28, 2024

MindMed to Participate at May Investor Conferences

Business Wire May 9, 2024

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

Business Wire May 9, 2024

MindMed Reports First Quarter 2024 Financial Results and Business Updates

Business Wire May 8, 2024